Skip to main navigation Skip to search Skip to main content

Abstract

CSNK2B encodes for casein kinase II subunit beta (CK2β), the regulatory subunit of casein kinase II (CK2), which is known to mediate diverse cellular pathways. Variants in this gene have been recently identified as a cause of Poirier-Bienvenu neurodevelopmental syndrome (POBINDS), but functional evidence is sparse. Here, we report five unrelated individuals: two of them manifesting POBINDS, while three are identified to segregate a new intellectual disability-craniodigital syndrome (IDCS), distinct from POBINDS. The three IDCS individuals carried two different de novo missense variants affecting the same codon of CSNK2B. Both variants, NP_001311.3; p.Asp32His and NP_001311.3; p.Asp32Asn, lead to an upregulation of CSNK2B expression at transcript and protein level, along with global dysregulation of canonical Wnt signaling. We found impaired interaction of the two key players DVL3 and β-catenin with mutated CK2β. The variants compromise the kinase activity of CK2 as evident by a marked reduction of phosphorylated β-catenin and consequent absence of active β-catenin inside nuclei of the patient-derived lymphoblastoid cell lines (LCLs). In line with these findings, whole-transcriptome profiling of patient-derived LCLs harboring the NP_001311.3; p.Asp32His variant confirmed a marked difference in expression of genes involved in the Wnt signaling pathway. In addition, whole-phosphoproteome analysis of the LCLs of the same subject showed absence of phosphorylation for 313 putative CK2 substrates, enriched in the regulation of nuclear β-catenin and transcription of the target genes. Our findings suggest that discrete variants in CSNK2B cause dominant-negative perturbation of the canonical Wnt signaling pathway, leading to a new craniodigital syndrome distinguishable from POBINDS.

Original languageEnglish
Article number100111
JournalHuman Genetics and Genomics Advances
Volume3
Issue number3
DOIs
StatePublished - 14 Jul 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors

Funding

We are grateful to the parents of affected individuals, particularly the mother of subject 5, for their contribution and showing willingness to be part of the study. For technical help, we thank Ingelore Bäßmann from CCG, University of Cologne. We also thank Wolfgang Höhne for critical comments on the manuscript. We are indebted to Carien Niessen (CECAD, University of Cologne) for providing GFP-CTNNB1 plasmid. For services of MS and phosphoproteome profiling, we are thankful to CECAD, University of Cologne. This work was supported by the Center for Molecular Medicine Cologne (CMMC) (Projects 38-RP and C12; 2635/8029/01 and 2635/8326/01 to P.N. and M.S.H.) and the Koeln Fortune Program (Faculty of Medicine, University of Cologne; 381/2020 to M.S.H.). For subject 7, phenotypic analyses were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and were funded by the National Human Genome Research Institute ; National Eye Institute ; National Heart, Lung and Blood Institute grant UM1 HG008900 ; and National Human Genome Research Institute grant R01 HG009141 . The Rare Disease Flagship acknowledges financial support from the Royal Children’s Hospital Foundation , Murdoch Children’s Research Institute , and Harbig Foundation . This work was also supported by the German Research Foundation (DFG) (grant NI 643/4-2 to K.N.). We are grateful to the parents of affected individuals, particularly the mother of subject 5, for their contribution and showing willingness to be part of the study. For technical help, we thank Ingelore B??mann from CCG, University of Cologne. We also thank Wolfgang H?hne for critical comments on the manuscript. We are indebted to Carien Niessen (CECAD, University of Cologne) for providing GFP-CTNNB1 plasmid. For services of MS and phosphoproteome profiling, we are thankful to CECAD, University of Cologne. This work was supported by the Center for Molecular Medicine Cologne (CMMC) (Projects 38-RP and C12; 2635/8029/01 and 2635/8326/01 to P.N. and M.S.H.) and the Koeln Fortune Program (Faculty of Medicine, University of Cologne; 381/2020 to M.S.H.). For subject 7, phenotypic analyses were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and were funded by the National Human Genome Research Institute; National Eye Institute; National Heart, Lung and Blood Institute grant UM1 HG008900; and National Human Genome Research Institute grant R01 HG009141. The Rare Disease Flagship acknowledges financial support from the Royal Children's Hospital Foundation, Murdoch Children's Research Institute, and Harbig Foundation. This work was also supported by the German Research Foundation (DFG) (grant NI 643/4-2 to K.N.). The authors declare no competing interests.

FundersFunder number
CECAD
Carien Niessen
Center for Molecular Medicine Cologne2635/8326/01, 2635/8029/01
Harbig Foundation
Harvard Center for Mendelian Genomics
National Heart, Lung, and Blood InstituteR01 HG009141, UM1 HG008900
National Human Genome Research Institute
National Eye Institute
Broad Institute
Murdoch Children's Research Institute
Royal Children's Hospital Foundation
Deutsche ForschungsgemeinschaftNI 643/4-2
Universität zu Köln381/2020

    Keywords

    • CK2
    • CK2α
    • CK2β
    • CSNK2B
    • DVL3
    • GestaltMatcher
    • POBINDS
    • Wnt signaling
    • intellectual disability-craniodigital syndrome
    • whole transcriptome profiling
    • whole-phosphoproteome profiling
    • β-catenin

    Fingerprint

    Dive into the research topics of 'De novo variants of CSNK2B cause a new intellectual disability-craniodigital syndrome by disrupting the canonical Wnt signaling pathway'. Together they form a unique fingerprint.

    Cite this